“Polymeric Nanoparticle-Mediated Delivery of Oncolytic Measles Virus for Targeted Therapy in Cervical Cancer” (2024) Pharmaceutical Communications, 3(1), pp. 45–53. doi:10.55627/pharma.003.001.0887.